Richard Fedorak

List of Publications by Citations

Source: https://exaly.com/author-pdf/5928115/richard-fedorak-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250 23,240 149 70 h-index g-index citations papers 6.33 6.4 251 25,994 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
250	Infliximab maintenance therapy for fistulizing Crohnß disease. <i>New England Journal of Medicine</i> , 2004 , 350, 876-85	59.2	1727
249	Vedolizumab as induction and maintenance therapy for Crohnß disease. <i>New England Journal of Medicine</i> , 2013 , 369, 711-21	59.2	1328
248	Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohnß disease: the CLASSIC-I trial. <i>Gastroenterology</i> , 2006 , 130, 323-33; quiz 591	13.3	1305
247	Methotrexate for the treatment of Crohnß disease. The North American Crohnß Study Group Investigators. <i>New England Journal of Medicine</i> , 1995 , 332, 292-7	59.2	782
246	Adalimumab for maintenance treatment of Crohnß disease: results of the CLASSIC II trial. <i>Gut</i> , 2007 , 56, 1232-9	19.2	715
245	Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , 1999 , 116, 1107-14	13.3	636
244	Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. <i>New England Journal of Medicine</i> , 2005 , 352, 2499-507	59.2	633
243	A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohnß disease. <i>Gastroenterology</i> , 2008 , 135, 1130-41	13.3	614
242	Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohnß Relapse Prevention Trial Study Group. <i>Gastroenterology</i> , 1994 , 106, 287-96	13.3	601
241	A comparison of methotrexate with placebo for the maintenance of remission in Crohn® disease. North American Crohn® Study Group Investigators. <i>New England Journal of Medicine</i> , 2000 , 342, 1627-3	32 ^{59.2}	593
240	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011 , 60, 780-7	19.2	576
239	VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1539-46	0.7	551
238	Natalizumab for the treatment of active Crohnß disease: results of the ENCORE Trial. <i>Gastroenterology</i> , 2007 , 132, 1672-83	13.3	505
237	A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohnß disease. <i>Gastroenterology</i> , 2005 , 129, 807-18	13.3	491
236	The epidemiology of inflammatory bowel disease in Canada: a population-based study. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1559-68	0.7	459
235	Multiple doses of intravenous interleukin 10 in steroid-refractory Crohnß disease. Crohnß Disease Study Group. <i>Gastroenterology</i> , 1997 , 113, 383-9	13.3	427
234	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohnß disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000. 119, 1473-82	13.3	427

(2015-2000)

233	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohnß disease. Crohnß Disease IL-10 Cooperative Study Group. <i>Gastroenterology</i> , 2000 , 119, 1461-72	13.3	376
232	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , 2015 , 148, 1035-1058.e3	13.3	251
231	Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with CrohnB disease. <i>Gastroenterology</i> , 2014 , 146, 681-688.e1	13.3	237
230	Treatment of active Crohnß disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1370-7	6.9	236
229	World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. Journal of Clinical Gastroenterology, 2012 , 46, 468-81	3	226
228	Low-dose cyclosporine for the treatment of Crohnß disease. The Canadian Crohnß Relapse Prevention Trial Investigators. <i>New England Journal of Medicine</i> , 1994 , 330, 1846-51	59.2	222
227	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. <i>Inflammatory Bowel Diseases</i> , 1999 , 5, 262-70	4.5	204
226	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohnß disease. North American Azathioprine Study Group. <i>Gastroenterology</i> , 1999 , 117, 527-35	13.3	195
225	The bacteriology of biopsies differs between newly diagnosed, untreated, Crohnß disease and ulcerative colitis patients. <i>Journal of Medical Microbiology</i> , 2006 , 55, 1141-1149	3.2	194
224	Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , 2000 , 118, 1094-105	13.3	194
223	American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. <i>Gastroenterology</i> , 2007 , 133, 312-39	13.3	167
222	Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. <i>Gut</i> , 2017 , 66, 863-871	19.2	160
221	A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohnß disease. The Canadian Mesalamine for Remission of Crohnß Disease Study Group. <i>Gastroenterology</i> , 1997 , 112, 1069-77	13.3	146
220	Treatment of diabetic diarrhea with clonidine. <i>Annals of Internal Medicine</i> , 1985 , 102, 197-9	8	142
219	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2015 , 63, 320-8	13.4	141
218	Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. <i>Gastroenterology</i> , 1997 , 113, 151-9	13.3	141
217	Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. <i>Gastroenterology</i> , 2015 , 148, 1311-9.e6	13.3	140
216	The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for CrohnB disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 928-35.e2	6.9	134

215	Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 252-62	6.1	132
214	Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. <i>Gastroenterology</i> , 1990 , 98, 615-25	13.3	131
213	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014 , 46, 1131-4	36.3	130
212	Probiotics and the management of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2004 , 10, 286-99	4.5	129
211	Certolizumab pegol in patients with moderate to severe Crohn® disease and secondary failure to infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 688-695.e2	6.9	126
210	Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2007 , 85, 816-23	7	122
209	A randomised phase I study of etrolizumab (rhuMAb \blacksquare) in moderate to severe ulcerative colitis. <i>Gut</i> , 2013 , 62, 1122-30	19.2	108
208	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohnß disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1232-1243	6.1	101
207	Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 359-64	4.5	100
206	Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005 , 19, 235-44		100
205	Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. <i>Journal of Crohnls and Colitis</i> , 2012 , 6, 267-75	1.5	99
204	Recommendations for probiotic use2008. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42 Suppl 2, S104-6	83	99
203	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 760-8	4.5	96
202	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <i>Current Opinion in Pharmacology</i> , 2005 , 5, 596-603	5.1	96
201	Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 34-9	3	91
200	Probiotics and prebiotics in gastrointestinal disorders. <i>Current Opinion in Gastroenterology</i> , 2004 , 20, 146-55	3	90
199	Review article: a clinician guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 447-59	6.1	84
198	Endpoints for clinical trials evaluating disease modification and structural damage in adults with CrohnB disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1599-604	4.5	84

197	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. <i>Journal of Crohnls and Colitis</i> , 2013 , 7, e42-8	1.5	83	
196	Environment and the inflammatory bowel diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013 , 27, e18-24		83	
195	Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. <i>Journal of Proteome Research</i> , 2009 , 8, 5550-8	5.6	82	
194	Metabolomics and detection of colorectal cancer in humans: a systematic review. <i>Future Oncology</i> , 2010 , 6, 1395-406	3.6	81	
193	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 773-7	27·4	75	
192	Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4934-47	5.6	75	
191	Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 34-40	4.5	74	
190	Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1419-27	4.5	74	
189	Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 522-8	6.1	74	
188	Maintenance of clinical benefit in Crohnß disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 112	9 ⁶ .3 ¹ 4	74	
187	The frequency of vitamin D deficiency in adults with Crohn® disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003 , 17, 473-8		73	
186	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , 2000 , 118, A874	13.3	73	
185	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 205-14	4	72	
184	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. <i>Advanced Drug Delivery Reviews</i> , 2005 , 57, 303-16	18.5	71	
183	The buried gastrostomy bumper syndrome: prevention and endoscopic approaches to removal. <i>Gastrointestinal Endoscopy</i> , 1995 , 41, 505-8	5.2	71	
182	The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 629-38	6.1	70	
181	Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in CrohnB disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 122-32	6.9	70	
180	Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. <i>Circulation Research</i> , 1998 , 83, 1124-3	3 ^{15.7}	69	

179	Development and validation of an administrative case definition for inflammatory bowel diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012 , 26, 711-7		67
178	Probiotics in the treatment of inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 260-3	3	67
177	Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 1999 , 13, 1565-84	6.1	67
176	FK506 increases permeability in rat intestine by inhibiting mitochondrial function. <i>Gastroenterology</i> , 1995 , 109, 107-14	13.3	67
175	Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. <i>Gastrointestinal Endoscopy</i> , 2010 , 71, 44-9	5.2	66
174	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active CrohnB disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1209-18	4.5	62
173	Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. <i>Analytical Chemistry</i> , 2008 , 80, 5524-31	7.8	62
172	VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 237-42		62
171	Bones and Crohnß: risk factors associated with low bone mineral density in patients with Crohnß disease. <i>Inflammatory Bowel Diseases</i> , 2004 , 10, 220-8	4.5	62
170	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011 , 73, 1174-80	5.2	60
169	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnß Disease: Real-world Experience from a Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 833-839	4.5	59
168	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohnß disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1170-81	6.1	59
167	Onercept for moderate-to-severe Crohn® disease: a randomized, double-blind, placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 888-93	6.9	58
166	Experimental diabetic diarrhea in rats. <i>Gastroenterology</i> , 1986 , 91, 564-569	13.3	56
165	Distance management of inflammatory bowel disease: systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 829-42	5.6	55
164	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients nalle to anti-TNF therapy: an indirect treatment comparison meta-analysis. <i>Journal of Crohnls and Colitis</i> , 2014 , 8, 571-81	1.5	54
163	Exercise and inflammatory bowel disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 497-504		54
162	Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 340-6	4.5	52

(2018-2003)

161	Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. <i>Inflammatory Bowel Diseases</i> , 2003 , 9, 87-97	4.5	52
160	Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. <i>Journal of Crohnls and Colitis</i> , 2012 , 6, 207-	1 ¹ 4 ^{:5}	50
159	The physiology of adaptation to small bowel resection in the pig: an integrated study of morphological and functional changes. <i>Journal of Pediatric Surgery</i> , 1990 , 25, 650-7	2.6	50
158	The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 1657-64	3	49
157	Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1272-7	4	49
156	Recommendations for probiotic use. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 275-8	3	49
155	Endoscopic perforation rates at a Canadian university teaching hospital. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004 , 18, 221-6		49
154	Intestinal adaptation to diabetes. Altered Na-dependent nutrient absorption in streptozocin-treated chronically diabetic rats. <i>Journal of Clinical Investigation</i> , 1987 , 79, 1571-8	15.9	49
153	Anti-TNF Therapy Within 2 Years of CrohnB Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 870-9	4.5	48
152	Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 240-5	3	47
151	Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991 , 69, 480-7	2.4	46
150	Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 691-704	0.7	45
149	CliniciansPguide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015 , 29, 369-72	2.8	44
148	Phenotypic features of Crohnß disease associated with failure of medical treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 434-42.e1	6.9	43
147	Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohnß disease. <i>International Journal of Colorectal Disease</i> , 2008 , 23, 289-96	3	43
146	Postoperative Crohnß disease. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 765-77	4.5	43
145	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohnß disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , 2009 , 58, 1354-62	19.2	42
144	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohnß Disease. <i>Nutrients</i> , 2018 , 10,	6.7	42

143	Vertebral fractures and role of low bone mineral density in Crohn® disease. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 721-8	6.9	41
142	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013 , 77, 624-30	5.2	40
141	A budesonide prodrug accelerates treatment of colitis in rats. <i>Gut</i> , 1994 , 35, 1439-46	19.2	40
140	Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. <i>Gastroenterology</i> , 2012 , 143, 1461-9	13.3	39
139	The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. <i>Gastroenterology Clinics of North America</i> , 2005 , 34, 465-82, ix	4.4	38
138	Crohnß disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. <i>Journal of Crohnls and Colitis</i> , 2014 , 8, 1454-63	1.5	37
137	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2006 , 8, 486-98	5	37
136	Intestinal function following allogeneic small intestinal transplantation in the rat. <i>Transplantation</i> , 1992 , 53, 264-71	1.8	36
135	Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2012 , 3, e19	4.2	35
134	Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. <i>Gastroenterology</i> , 1995 , 108, 1688-99	13.3	35
133	Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats. <i>American Journal of Physiology - Renal Physiology</i> , 1991 , 261, G58.	5 ⁵ 9 ¹ 1	34
132	Tumor necrosis factor-Imonoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. <i>Gastroenterology Clinics of North America</i> , 2010 , 39, 543-57	4.4	33
131	Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohnß disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009 , 23, 185-202		33
130	Adalimumab dose escalation is effective for managing secondary loss of response in CrohnB disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1044-55	6.1	32
129	A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. <i>Gastroenterology</i> , 1994 , 106, 405-13	13.3	32
128	Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1248-54	6.1	31
127	Understanding why probiotic therapies can be effective in treating IBD. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42 Suppl 3 Pt 1, S111-5	3	31
126	Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA. <i>PLoS ONE</i> , 2012 , 7, e37932	3.7	30

(2008-2018)

125	Heterogeneity in Definitions of Efficacy and Safety Endpoints[for[Clinical Trials of Crohn® Disease: Alsystematic[Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1407-1419.e22	6.9	29
124	Long-term response rates to infliximab therapy for Crohnß disease in an outpatient cohort. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009 , 23, 348-52		29
123	Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 947-54	4.5	29
122	A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 181-7	6.1	28
121	Small intestinal function following syngeneic transplantation in the rat. <i>Journal of Surgical Research</i> , 1996 , 61, 379-84	2.5	28
120	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 637-647.e13	6.9	27
119	Adalimumab for orbital myositis in a patient with Crohnß disease who discontinued infliximab: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2013 , 13, 59	3	27
118	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 675-82	3	27
117	Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. <i>Clinical and Translational Gastroenterology</i> , 2014 , 5, e54	4.2	27
116	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. <i>Inflammatory Bowel Diseases</i> ,5, 262-270	4.5	27
115	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017 , 7, e016146	3	26
114	A machine-learned predictor of colonic polyps based on urinary metabolomics. <i>BioMed Research International</i> , 2013 , 2013, 303982	3	26
113	In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. <i>Gastroenterology</i> , 1988 , 94, 1343-50	13.3	25
112	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohnß disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3347-51	5.6	24
111	Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 465-71; quiz 371	6.9	24
110	Normal Breast Milk Limits the Development of Colitis in IL-10-Deficient Mice. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 390-8	4.5	24
109	Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 905-13	4	24
108	Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent?. <i>Journal of Medical Microbiology</i> , 2008 , 57, 111-1	1 ³ 7 ²	23

107	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , 1995 , 38, 403-12	10.3	23
106	Tacrolimus (FK506)its effects on intestinal glucose transport. <i>Transplantation</i> , 1996 , 61, 630-4	1.8	23
105	Health care resource use and costs in Crohnß disease before and after infliximab therapy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011 , 25, 497-502		22
104	Naturally occurring glycoalkaloids in potatoes aggravate intestinal inflammation in two mouse models of inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3078-85	4	22
103	Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. <i>Metabolites</i> , 2017 , 7,	5.6	21
102	Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in CrohnB disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004 , 18, 503-8		21
101	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn® Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018 , 1, 115-123	0.5	21
100	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2012 , 41, 821-42	4.4	20
99	Antidiarrheal therapy. Prospects for new agents. <i>Digestive Diseases and Sciences</i> , 1987 , 32, 195-205	4	20
98	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1578-1596	6.1	19
97	Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns. <i>BMJ Open</i> , 2014 , 4, e003689	3	19
96	Drug-disease interaction: Crohnß disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 787-97	3.8	19
95	CrohnB disease genotypes of patients in remission vs relapses after infliximab discontinuation. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5058-64	5.6	19
94	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , 2003 , 124, A377	13.3	19
93	Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. <i>Gastroenterology</i> , 1986 , 91, 564-9	13.3	19
92	Molecular patterns in human ulcerative colitis and correlation with response to infliximab. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2353-63	4.5	18
91	Epithelial cell extrusion leads to breaches in the intestinal epithelium. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 912-21	4.5	18
90	Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 677-81	3.9	18

89	Food consistency effects of quarg in lactose malabsorption. <i>International Dairy Journal</i> , 1992 , 2, 257-269 ₃ .	.5	18	
88	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. <i>World Journal of Gastrointestinal Pathophysiology</i> , 3. 2015 , 6, 181-92	.2	18	
87	Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn® Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 92-9	.5	18	
86	An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animalB first exposure to faecal bacteria and antigens. <i>Clinical and Experimental Immunology</i> , 2010 , 6.161, 187-96	.2	17	
85	Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010 , 24, 651-5		17	
84	Oral vanadate reduces Na(+)-dependent glucose transport in rat small intestine. <i>Diabetes</i> , 1993 , 42, 1126	3)2	17	
83	Helicobacter pylori infection in Canadaß arctic: searching for the solutions. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 912-6		16	
82	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017 , 23, 3890-3899	.6	16	
81	Nutritional and intestinal effects of the novel immunosuppressive agents: deoxyspergualin, rapamycin, and mycophenolate mofetil. <i>Clinical Biochemistry</i> , 1996 , 29, 363-9	.5	15	
80	Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1989 , 38, 43-8	.8	15	
79	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2020 , 65, 2354-2372		14	
78	A randomized trial of topical anesthesia comparing lidocaine versus lidocaine plus xylometazoline for unsedated transnasal upper gastrointestinal endoscopy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010 , 24, 317-21		14	
77	TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10358-66	.6	14	
76	A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn® Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 861-870	.5	13	
75	The NOD2-Smoking Interaction in Crohnß Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. <i>EBioMedicine</i> , 2017 , 21, 188-196.	.8	13	
74	Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 767-770	.6	13	
73	Predicting, treating and preventing postoperative recurrence of Crohn® disease: the state of the field. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011 , 25, 140-6		13	
72	The role of probiotics in management of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , 2007 , 9, 393-400		13	

71	Increased permeability occurs in rat ileum following induction of pan-colitis. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 405-11	4	13
70	Adaptation of intestinal glucose transport in rats with diabetes mellitus occurs independent of hyperphagia. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991 , 69, 1143-8	2.4	13
69	Don® Forget the Doctor: GastroenterologistsPPreferences on the Development of mHealth Tools for Inflammatory Bowel Disease. <i>JMIR MHealth and UHealth</i> , 2015 , 3, e5	5.5	13
68	Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1359-67	4.5	12
67	Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease. <i>PLoS ONE</i> , 2013 , 8, e67654	3.7	12
66	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohnß Disease. <i>Gastroenterology</i> , 2010 , 138, S-167-S-168	13.3	12
65	Does smoking reduce infliximabß effectiveness against Crohnß disease?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009 , 23, 121-5		12
64	Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 429-36	4.5	12
63	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016 , 2016, 2079582	2.8	12
62	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohnß Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1515-1524.e4	6.9	12
61	Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. <i>International Journal of Colorectal Disease</i> , 2017 , 32, 741-743	3	11
60	Jejunum is preferable for construction of a Bianchi bowel-lengthening procedure in swine short bowel. <i>Journal of Pediatric Surgery</i> , 1993 , 28, 102-9	2.6	11
59	Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. A limited systemic effect. <i>Digestive Diseases and Sciences</i> , 1989 , 34, 567-72	4	11
58	Diabetes mellitus and glucagon alter ouabain-sensitive Na(+)-K(+)-ATPase in rat small intestine. <i>Diabetes</i> , 1991 , 40, 1603-10	0.9	11
57	Incidence Rates for Surgery in Crohnß Disease Have Decreased: A Population-based Time-trend Analysis. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1909-1916	4.5	11
56	Fecal Microbial Transplant After Ileocolic Resection Reduces Ileitis but Restores Colitis in IL-10-/-Mice. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1479-90	4.5	10
55	Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015 , 29, 309-14	2.8	10
54	Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1871-8.e8	6.9	10

53	Risedronate improves bone mineral density in Crohnß disease: a two year randomized controlled clinical trial. <i>Journal of Crohnls and Colitis</i> , 2012 , 6, 777-86	1.5	10
52	Acetic acid-induced colitis results in bystander ileal injury. <i>Agents and Actions</i> , 1993 , 38, 76-84		10
51	Probiotics in the management of ulcerative colitis. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 688-90	0.7	10
50	Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2483-2493	4.5	9
49	Is it time to re-classify Crohn® disease?. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18 Suppl, 99-106	2.5	9
48	Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1992 , 45, 275-81	2.8	9
47	Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation. <i>Inflammatory Bowel Diseases</i> , 2017 , 24, 101-110	4.5	8
46	Early experience with unsedated ultrathin 4.9 mm transnasal gastroscopy: a pilot study. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 917-22		8
45	A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 750-7	4.5	8
44	Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. <i>PLoS ONE</i> , 2013 , 8, e67017	3.7	7
43	Review and clinical perspectives for the use of infliximab in ulcerative colitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 261-72		7
42	Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. <i>Gastroenterology</i> , 1992 , 102, 1229-35	13.3	7
41	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1895-902	4	7
40	Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohnß disease. <i>Scientific Reports</i> , 2018 , 8, 9734	4.9	7
39	Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. <i>Metabolomics</i> , 2016 , 12, 1	4.7	6
38	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. <i>Digestive Diseases</i> , 2016 , 34, 112-21	3.2	6
37	Intravenous injection of endogenous microbial components abrogates DSS-induced colitis. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 345-54	4	6
36	Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. <i>Journal of Surgical Research</i> , 2012 , 178, 147-54	2.5	6

35	Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation study. <i>Clinical and Translational Gastroenterology</i> , 2011 , 2, e3	4.2	6
34	Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. <i>Microbial Ecology in Health and Disease</i> , 2009 , 21, 33-37		6
33	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. <i>Biopharmaceutics and Drug Disposition</i> , 1997 , 18, 681-95	1.7	6
32	Oropharyngeal Crohn® disease. Clinical and Experimental Gastroenterology, 2008, 1, 15-8	3.1	6
31	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016 , 2016, 5315798	2.8	6
30	Novel Microbial-Based Immunotherapy Approach for Crohnß Disease. <i>Frontiers in Medicine</i> , 2019 , 6, 170) 4.9	5
29	Neonatal exposure to fecal antigens reduces intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 899-906	4.5	5
28	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. <i>Gastroenterology</i> , 2016 , 150, e1-2	13.3	4
27	Inhibition of cholera-toxin-stimulated intestinal secretion by CGS 9343B in rats: a specific calmodulin inhibitor. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1989 , 8, 252-8	2.8	4
26	Insulin downregulates diabetic-enhanced intestinal glucose transport rapidly in ileum and slowly in jejunum. <i>Canadian Journal of Physiology and Pharmacology</i> , 1996 , 74, 1294-301	2.4	4
25	Pregnancy-Related Beliefs and Concerns of Inflammatory Bowel Disease Patients Modified After Accessing e-Health Portal. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, 27-35	0.5	4
24	A BACH2 Gene Variant Is Associated with Postoperative Recurrence of Crohnß Disease. <i>Journal of the American College of Surgeons</i> , 2018 , 226, 902-908	4.4	3
23	Murine ileocolic bowel resection with primary anastomosis. <i>Journal of Visualized Experiments</i> , 2014 , e52	1106	3
22	Patients with Active Luminal Crohnß Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1817-24	4.5	3
21	Celiac disease in children with inflammatory bowel disease: a prospective cohort study. <i>American Journal of Gastroenterology</i> , 2013 , 108, 455-6	0.7	3
20	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , 2007 , 102, S22-S28	0.7	3
19	Su1396 Crohnß Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab. <i>Gastroenterology</i> , 2014 , 146, S-457-S	-438	2
18	A Novel Highly Sensitive Test for Detecting Colon Cancer Using Spot Urine Metabolomics. <i>Gastroenterology</i> , 2011 , 140, S-40	13.3	2

LIST OF PUBLICATIONS

17	Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis. <i>PLoS ONE</i> , 2017 , 12, e0184660	3.7	2
16	Probiotics in the management of inflammatory bowel disease. <i>MedGenMed: Medscape General Medicine</i> , 2005 , 7, 19		2
15	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD 2011 , 123-150		2
14	Commentary: larazotide acetate - an exciting new development for coeliac patients? AuthorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 496-7	6.1	1
13	The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. <i>PharmacoEconomics - Open</i> , 2019 , 3, 591-597	2.1	Ο
12	Conservative approach to severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2004 , 36, 4-6	3.3	O
11	Biosimilars in the Treatment of Inflammatory Bowel Disease 2017 , 471-479		
10	A 29-year-old woman with Crohn disease considering pregnancy. <i>Cmaj</i> , 2016 , 188, 131-132	3.5	
9	Urine-based test for detection of colonic polyps: the coming of age. Colorectal Cancer, 2014, 3, 239-24	1 0.8	
8	Short Bowel Syndrome1295-1321		
7	Canadian Digestive Health Foundation: Interview with the New President, Dr Richard Fedorak. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 345-346		
6	CD4+CD25+ regulatory T cells have divergent effects on intestinal inflammation in IL-10 gene-deficient mice. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 1544-52	4	
5	A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. <i>American Journal of Physiology - Renal Physiology</i> , 1995 , 269, G210-8	5.1	
4	Probiotic Therapies for IBD. <i>Gastroenterology and Hepatology</i> , 2007 , 3, 180-1	0.7	
3	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , 2007 , 102, 22-28	0.7	
2	Probiotics in Ulcerative Colitis 2009 , 181-194		
1	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , 1995 , 38, 403-412	10.3	